DK1833507T3 - Sammensætning til immunisering mod mykobakterier - Google Patents

Sammensætning til immunisering mod mykobakterier

Info

Publication number
DK1833507T3
DK1833507T3 DK06700223.8T DK06700223T DK1833507T3 DK 1833507 T3 DK1833507 T3 DK 1833507T3 DK 06700223 T DK06700223 T DK 06700223T DK 1833507 T3 DK1833507 T3 DK 1833507T3
Authority
DK
Denmark
Prior art keywords
antigen
composition
immunization against
vector expressing
against mycobacteria
Prior art date
Application number
DK06700223.8T
Other languages
English (en)
Inventor
Helen Mcshane
Ansar A Pathan
Adrian Hill
Sarah C Gilbert
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Priority claimed from PCT/GB2006/000023 external-priority patent/WO2006072787A1/en
Application granted granted Critical
Publication of DK1833507T3 publication Critical patent/DK1833507T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Techniques For Improving Reliability Of Storages (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK06700223.8T 2005-01-05 2006-01-05 Sammensætning til immunisering mod mykobakterier DK1833507T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0500102.9A GB0500102D0 (en) 2005-01-05 2005-01-05 Method for generating a memory t cell response
US64980405P 2005-02-03 2005-02-03
PCT/GB2006/000023 WO2006072787A1 (en) 2005-01-05 2006-01-05 Compositions for immunizing against mycobacterium

Publications (1)

Publication Number Publication Date
DK1833507T3 true DK1833507T3 (da) 2011-07-11

Family

ID=34179184

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06700223.8T DK1833507T3 (da) 2005-01-05 2006-01-05 Sammensætning til immunisering mod mykobakterier

Country Status (12)

Country Link
US (1) US7850979B2 (da)
CN (2) CN101115500A (da)
AT (1) ATE501727T1 (da)
DE (1) DE602006020679D1 (da)
DK (1) DK1833507T3 (da)
ES (1) ES2364698T3 (da)
GB (1) GB0500102D0 (da)
PT (1) PT1833507E (da)
RS (1) RS51815B (da)
SI (1) SI1833507T1 (da)
UA (1) UA93665C2 (da)
ZA (1) ZA200706389B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9915055A (pt) * 1998-11-04 2001-08-07 Isis Innovation Teste diagnóstico de tuberculose
US20100226998A1 (en) * 2009-03-05 2010-09-09 Ultradent Products, Inc. Anti-viral and anti-microbial dental operative material and methods
MX344052B (es) * 2009-05-13 2016-12-02 Immport Therapeutics Inc Composiciones y metodos para antigenos inmunodominantes de mycobacterium tuberculosis.
MX345575B (es) * 2010-12-21 2017-02-03 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Micobacteria recombinante como vacuna.
WO2013158061A1 (en) * 2012-04-16 2013-10-24 Aeras Global Tb Vaccine Foundation Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof
CN102732480A (zh) * 2012-06-11 2012-10-17 中山大学 N-乙酰半胱氨酸对中央记忆性t细胞的绝对数量在体外扩增上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
CN1596126A (zh) * 2001-11-30 2005-03-16 埃西斯创新有限公司 疫苗

Also Published As

Publication number Publication date
DE602006020679D1 (de) 2011-04-28
ES2364698T3 (es) 2011-09-12
CN102580070A (zh) 2012-07-18
SI1833507T1 (sl) 2011-07-29
PT1833507E (pt) 2011-06-27
GB0500102D0 (en) 2005-02-09
US20080226678A1 (en) 2008-09-18
US7850979B2 (en) 2010-12-14
CN101115500A (zh) 2008-01-30
ATE501727T1 (de) 2011-04-15
ZA200706389B (en) 2008-08-27
UA93665C2 (ru) 2011-03-10
RS51815B (en) 2011-12-31

Similar Documents

Publication Publication Date Title
Chavda et al. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era
Khan DNA vaccines: roles against diseases
Delany et al. Vaccines for the 21st century
Ottenhoff et al. Vaccines against tuberculosis: where are we and where do we need to go?
Dietrich et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity
da Costa et al. Tuberculosis vaccines–state of the art, and novel approaches to vaccine development
EA200701440A1 (ru) Композиции для иммунизации против микобактерий
Zheng et al. Applications of bacillus Calmette–Guerin and recombinant bacillus Calmette–Guerin in vaccine development and tumor immunotherapy
Nel et al. Nano-enabled COVID-19 vaccines: meeting the challenges of durable antibody plus cellular immunity and immune escape
DK1833507T3 (da) Sammensætning til immunisering mod mykobakterier
EP2385059A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
GB2434367A (en) Improved vaccines
Matsuo et al. Mycobacterium bovis Bacille Calmette‐Guérin as a Vaccine Vector for Global Infectious Disease Control
Kaufmann Tuberculosis vaccine development at a divide
Soundarya et al. Current trends in tuberculosis vaccine
Bruffaerts et al. DNA vaccines against tuberculosis
Plotkin Six revolutions in vaccinology
Ranasinghe et al. Genetic heterologous prime–boost vaccination strategies for improved systemic and mucosal immunity
Villarreal et al. Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG
Stanberry et al. Vaccines of the future
Gillis et al. rBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B
Behar et al. Next generation: tuberculosis vaccines that elicit protective CD8+ T cells
WO2004043399A3 (en) Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
Hu et al. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines
Wu et al. DNA vaccine with discontinuous T‐cell epitope insertions into HSP65 scaffold as a potential means to improve immunogenicity of multi‐epitope Mycobacterium tuberculosis vaccine